NASDAQ$CCCC
C4 Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Before market open · Investor relations
Briefing
C4 Therapeutics Inc reported Q2 2024 financial results with revenue growth from collaboration agreements and reduced net loss compared to the prior year.
C4 Therapeutics Inc achieved $12.0 million in revenue from collaboration agreements during the three months ended June 30, 2024. The company reported a net loss of $17.7 million and an operating loss of $21.4 million, with research and development expenses at $23.8 million. Cash, cash equivalents, and marketable securities totaled $295.7 million at quarter end.
- Revenue from collaboration agreements increased to $12.0 million in Q2 2024 from $2.7 million in Q2 2023, driven by milestones from Biogen and progress on new agreements.
- Net loss narrowed to $17.7 million in Q2 2024 from $35.9 million in Q2 2023, supported by higher other income and lower operating expenses.
- Research and development expenses decreased to $23.8 million in Q2 2024 from $29.9 million in Q2 2023 due to restructuring and program prioritization.
- The company maintained a strong liquidity position with $295.7 million in cash, cash equivalents, and marketable securities as of June 30, 2024.
Headline financials
Revenue & EPS history
C4 Therapeutics · Revenue · Quarterly
$12M
Revenue by segment
C4 Therapeutics · $6.46M total across 4 segments · Q2 2025
- MKDG Agreement$3.43M—53.0%
- Roche Agreement$1.93M—29.9%
- Merck Agreement$1.05M—16.2%
- Betta Agreement$54K—0.8%
Forward guidance
The company continues to advance its clinical pipeline with ongoing Phase 1/2 trials for cemsidomide and CFT1946, supported by collaboration revenues.
Tailwinds
- Increased collaboration revenue from milestones and new agreements
- Reduced net loss and operating expenses year-over-year
- Strong cash position extending runway into 2027
Headwinds
- Continued net losses expected as clinical development progresses
- Dependence on collaboration partners for revenue and development
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
+2.2%
Avg return
Earnings day
+4.1%
Avg return
5 days after
-1.1%
Avg return
30 days after
40%
10 / 25 earnings
Positive
+30.9%
Q2 2025
Best reaction
-10.0%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q2 2025 | +30.9% | — | — | |
| Q1 2026 | +0.0% | +13.0% | +22.2% | |
| Q4 2025 | +0.4% | +17.4% | +13.9% | |
| Q3 2025 | -2.0% | -10.0% | +8.0% | |
| Q1 2025 | -0.7% | -1.4% | +21.7% | |
| Q4 2024 | -1.9% | -10.2% | -34.0% | |
| Q3 2024 | +1.4% | +10.1% | -17.7% | |
| Q1 2024 | +0.1% | -9.1% | -31.4% | |
| Q4 2023 | +24.0% | +34.5% | +13.4% | |
| Q3 2023 | -6.0% | +21.5% | +7.4% | |
| Q2 2023 | -1.7% | -3.1% | -33.8% | |
| Q1 2023 | +4.8% | +5.6% | +8.0% | |
| Q4 2022 | -10.0% | -11.0% | -40.2% | |
| Q3 2022 | -8.1% | -6.4% | -11.8% | |
| Q2 2022 | +16.7% | +6.9% | -8.7% | |
| Q1 2022 | -8.1% | -19.3% | -24.4% | |
| Q4 2021 | +13.9% | +13.9% | +24.3% | |
| Q3 2021 | -4.6% | -7.3% | -23.6% | |
| Q2 2021 | +8.0% | +5.6% | +33.6% | |
| Q1 2020 | -0.6% | +7.4% | +20.4% | |
| Q1 2021 | -0.6% | +7.4% | +20.4% | |
| Q2 2020 | +9.6% | +7.2% | -19.8% | |
| Q3 2019 | -3.7% | +8.3% | +8.3% | |
| Q3 2020 | -3.7% | +8.3% | +8.3% | |
| Q4 2019 | -3.7% | +8.3% | +8.3% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro